Herantis Pharma dosed first patients in final cohort of Phase 1b trial for Parkinson's disease.

From GlobeNewswire: 2025-05-13 02:05:00

Herantis Pharma Plc has dosed the first patients in the final cohort of its Phase 1b clinical trial for HER-096, a potential treatment for Parkinson’s disease. The trial aims to assess safety, tolerability, and pharmacokinetics, with topline data expected in September 2025. The drug has disease-modifying potential and is funded by the Michael J. Fox Foundation for Parkinson’s Research and Parkinson’s UK. HER-096 is designed to mimic the activity of CDNF protein and cross the blood-brain barrier for convenient subcutaneous administration, offering hope for patients with this debilitating condition. More information about the trial can be found on the company’s website.



Read more at GlobeNewswire: First patients dosed in final cohort of Phase 1b clinical